Company intelligence / Profile preview

GV20 Oncotherapy

Cambridge, Massachusetts, USAprnewswire.com ↗

Ownership: Private
Development stage: Preclinical

Overview

GV20 Oncotherapy has developed a proprietary AI-driven antibody drug discovery engine that integrates high-throughput functional genomics and artificial intelligence to identify novel cancer immunology drug targets. Their lead program, an AI-designed monoclonal antibody targeting the immune checkpoint IGSF8, represents a first-in-class approach now advancing toward clinical trials. The company’s pipeline includes several preclinical-stage immuno-oncology candidates against novel or challenging targets.

Therapeutic areas: Oncology
Modalities: Fully human monoclonal antibodiesAntibody therapeuticsGene editing (for target discovery)Bioinformatics/AI-driven drug design
Industry: Biotech

Beyond the preview

Go deeper on GV20 Oncotherapy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GV20 Oncotherapy.

Explore the full profile